| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net earnings | 115,620 | 75,331 |
| Depreciation and amortization | 33,969 | 22,417 |
| Stock compensation expense | 14,298 | 9,648 |
| Deferred income taxes | -273 | -124 |
| Provision for credit losses | -118 | -108 |
| Unrealized gain on foreign currency transactions and deferred compensation | 1,207 | 843 |
| (gain) loss on disposal of assets and asset impairment | 94 | 117 |
| Change in fair value of contingent consideration liability | 0 | 0 |
| Accounts receivable | 8,900 | 13,262 |
| Inventories | -2,622 | 13,074 |
| Prepaid expenses and other current assets | -24 | 618 |
| Accounts payable and accrued expenses | -9,024 | 8,682 |
| Income taxes | 1,440 | -4,410 |
| Other | 924 | 187 |
| Net cash provided by operating activities | 149,281 | 83,709 |
| Capital expenditures and intangible assets acquired | 27,275 | 12,372 |
| Cash paid for acquisitions, net of cash acquired | 323 | 323 |
| Proceeds from sale of assets | 267 | 267 |
| Investment in affiliates | 144 | 105 |
| Net cash used in investing activities | -27,475 | -12,533 |
| Proceeds from revolving loan | 70,000 | 63,000 |
| Principal payments on revolving loan | 106,000 | 63,000 |
| Principal payments on finance leases | 145 | 97 |
| Proceeds from stock options exercised | 6,867 | 6,222 |
| Dividends paid | 28,276 | 28,265 |
| Repurchases of common stock | 54,008 | 38,589 |
| Net cash used in financing activities | -111,562 | -60,729 |
| Effect of exchange rate changes on cash | 5,334 | 5,465 |
| Increase in cash and cash equivalents | 15,578 | 15,912 |
| Cash and cash equivalents at beginning of period | 49,515 | - |
| Cash and cash equivalents at end of period | 65,093 | - |
BALCHEM CORP (BCPC)
BALCHEM CORP (BCPC)